Psoriasis

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.

Psoriasis severity and treatment outcomes were found to differ across US geographic regions, in which the East South Central and West South Central regions were associated with the greatest frequencies of very severe disease burden and decreased likelihood of achieving targeted response within 6 months of initiating biologic therapy.

Childhood psoriasis was found to be significantly associated with environmental tobacco smoke exposure, whereas intrauterine smoking exposure was not associated with an increased risk in pediatric populations.

Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.

The top 5 most-read psoriasis articles of 2021 on AJMC.com covered risk factors involved in the pathogenesis and treatment of psoriatic disease and cost considerations for treatment.

A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.

Patients with comorbid nonalcoholic fatty liver disease (NAFLD) and chronic plaque psoriasis were shown to have significantly lower estimated glomerular filtration rate levels and greater prevalence of more advanced chronic kidney disease.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.

Nail involvement was shown to reduce the effectiveness of ustekinumab in the treatment of moderate to severe psoriasis, whereas secukinumab exhibited overall higher efficacy than ustekinumab and similar response rates regardless of nail involvement.

Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.

Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).

Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.

Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.

Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.

Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.

Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.

A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.

This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.

Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.

Pregnant women with psoriasis were found to be at increased risk of experiencing preterm birth and Cesarean delivery, with patients undergoing anti-rheumatic treatment during their first pregnancy indicated to be at significantly greater risk.